Simultaneous and niche skills sought amid evolution in clinical data management.
Competency-based and other creative approaches are needed to address the battle for talent in the clinical research workforce.
With the number of clinical trials and sponsors increasing every year, meeting enrollment requirements and timelines becomes harder and harder. Please join Almac Clinical Technologies and Exostar as they discuss solutions to attract and retain the right resources to meet your requirements and timelines. Live: Thursday, Aug. 27, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Aug. 27, 2021.
Jon Ernst (Vice President, In-Home Solutions, Decentralized Clinical Trials) discusses today's clinical trial landscape.
Sponsors and CROs have historically been responsible for ensuring full chain of custody for their own clinical supply even though the clinical supply is typically outside of their control. It is the burden of the Sponsors and CROs to determine the most efficient way to do that. An eClinical Supply Chain Management platform provides Sponsors and CROs with the assurance that they are meeting their regulatory requirement of full chain of custody and more importantly ensures that all needed clinical supplies are available and all samples get where and when they are needed.
A shared partnership culture is critical in navigating today’s complex terrain.
Although executive enthusiasm for decentralization of clinical trials has grown significantly, operationalizing these models requires meticulous planning and risk-based quality management.
While the world focuses on COVID-19, this article provides insight on the current state of the market for antimicrobial resistant (AMR) medicines.
Multicentric studies on diarrhea are essential for comprehending its epidemiology, causes, and treatment outcomes.
Successful oncolytic virus immunotherapy clinical development requires unique features that focus on viral biology and host immune response.
A framework to understand the different approaches of trial matching solutions and the major operational and workflow challenges that all matching solutions share.
The Phase II KRAKEN trial demonstrated that muvalaplin, Eli Lilly's first-in-class oral small molecule inhibitor, significantly reduces lipoprotein(a) levels with minimal adverse effects, offering a promising new approach to addressing a major cardiovascular risk factor.
Tufts CSDD study breaks down state of the talent pipeline from lens of senior leaders.
Identifying the ‘significant six’ areas of clinical study conduct to mitigate risk.
A discussion of the regulatory history behind audit trails and its interpretation as it relates to clinical research data originating or residing in EDC or eCOA systems.
How the digital environment can transform drug development space.
Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.
How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.
The approach of the Cancer Research UK Centre for Drug Development.
Renewed interest in psychedelic research shows great promise for patients in need of more effective therapies.
In light of scant published data from sponsors and contract research organizations on site activation and recruitment challenges following the COVID-19 pandemic, the primary objective of this research is to revisit the results of recruitment and retention tactics in studies conducted in 2012 and 2019.
Bringing clinical trials to patients’ homes can address existing site-based challenges.
Considering caregiver-supported trials to improve patient retention and outcomes.
To overcome sponsor-related challenges and work to successfully secure more trials, there are tactical steps CROs can take.
How optimizing RBQM risk detection reduces the efforts caused by false signals.
How Clinical Research Malaysia sped up CTA turnaround using a web-based system.
First-of-its-kind consortium dedicated to accelerating new medicines development through optimizing patient advocacy group—industry collaboration.
For advancement, pharma must focus on streamlining clinical operations.